Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Antares: Highlights from 2Q, 2019 Conference Call (ATRS, $3.29, Buy)

Introduction

I have heard encouraging comments on my recently announced approach of doing shorter, less pedantic reports on new companies. This…
Read more…

Antares Pharma: The Xyosted Launch Continues to Look Good (ATRS, Buy, $3.37)

Investment Thesis

The cornerstone of my positive investment thesis for Antares is Xyosted, which was fully launched in January 2019. While…
Read more…

Antares: Multiple New Product Launches Make for Extreme Complexity in Earnings Forecasts for 2019 to 2021 (ATRS, Buy, $3.59)

Investment Thesis in Brief:

In this report, I have put together an earnings forecast projecting EPS of (0.04) in 2019, $0.19…
Read more…

Antares Pharma: This Small, Emerging Biotechnology Company Is Poised for Explosive Growth Based on Five Major New Product Introductions by 2020 (ATRS, Buy, $3.02

Investment Thesis

Antares is one of my top recommendations based on its extremely impressive pipeline prospects. In a March 23, 2017…
Read more…